COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Mantle Irradiation for Hodgkin's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00165269
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : November 1, 2009
Brigham and Women's Hospital
Massachusetts General Hospital
Information provided by:
Dana-Farber Cancer Institute

Brief Summary:
The purpose of this study it to evaluate the effectiveness of radiation therapy limited to above the diaphragm in patients with pathological stage IA-IIA Hodgkin's disease.

Condition or disease Intervention/treatment Phase
Hodgkin's Disease Procedure: Mantle irradiation Phase 2

Detailed Description:
  • Eligble patients will receive a course of radiation therapy directed to above the diaphragm only.
  • Patients would have bloodwork and chest x-rays performed 4 times per year for the first two years, 3 times per year for the third year, and 2 times per year for the fourth and fifth years. After five years, yearly check-ups are performed.
  • In addition to the above follow-up, patients will receive, once or twice a year for the first 5 years, an abdominal-pelvic CT scan and/or gallium scan.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Mantle Irradiation for Selected Hodgkin's Disease Patients With Stage IA-IIA Disease
Study Start Date : May 1992
Actual Primary Completion Date : June 2000
Actual Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hodgkin Disease

Intervention Details:
  • Procedure: Mantle irradiation
    Limited to above the diaphragm

Primary Outcome Measures :
  1. To evaluate the risks and benefits of mantle field irradiation alone in treating Hodgkin disease patients. [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically Stage IA-IIA Hodgkin's disease
  • A negative staging laparotomy including splenectomy, biopsies of liver, paraortic nodal biopsies and palpitation of upper pelvic nodes
  • 18 years of age or older

Exclusion Criteria:

  • Patients with large mediastinal adenopathy
  • Patients with LD histology
  • Patients with "B" symptoms
  • Positive laparotomy
  • Subcarinal, hilar, or cardiac lymph node involvement

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00165269

Layout table for location information
United States, Massachusetts
Dana-Farber Cancer Center
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Peter Mauch, MD Dana-Farber Cancer Institute
Layout table for additonal information
Responsible Party: Peter Mauch, MD, Dana-Farber Cancer Institute Identifier: NCT00165269    
Other Study ID Numbers: 92-035
First Posted: September 14, 2005    Key Record Dates
Last Update Posted: November 1, 2009
Last Verified: October 2009
Keywords provided by Dana-Farber Cancer Institute:
Hodgkin's Disease Stage IA-IIA
mantle irradiation
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases